October 2024

TAIPEI, Oct. 20, 2024 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announced the successful completion of its Phase 1 single and multiple ascending dose (SAD/MAD) clinical study in Australia with linvemastat (FP-020), its novel, highly selective, oral smal

TAIPEI, Oct. 20, 2024 /PRNewswire/ — Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announced the successful completion of its Phase 1 single and multiple ascending dose (SAD/MAD) clinical study in Australia with linvemastat (FP-020), its novel, highly selective, oral smal

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: